Reviews

< Previous         Next >  
Induced Foxp3+ regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? Free
Qin Lan1,2,†, Huimin Fan1,†, Valerie Quesniaux3, Bernhard Ryffel3, Zhongmin Liu1,*, and Song Guo Zheng2,3,*
1Medicine Translation Center, Shanghai East Hospital, Tongji University, Shanghai 200120, China
2Division of Rheumatology and Immunology, Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
3UMR6218, Molecular Immunology, University and CNRS, 3b rue de la Ferollerie, Orleans F-45071, France *Correspondence to:Song Guo Zheng, E-mail: szheng@usc.edu; Zhong-Min Liu, E-mail: zhongmin_liu@sina.com
J Mol Cell Biol, Volume 4, Issue 1, February 2012, 22-28,  https://doi.org/November 22, 2011
Keyword: autoimmune and inflammatory diseases, immunoregulation, regulatory T cells, TGF-β, Foxp3, Th17 cells, atRA
Foxp3+ T regulatory cells (Tregs) consisting of natural and induced Treg subsets play a crucial role in the maintenance of immune homeostasis against self-antigen. The actions designed to correct defects in numbers or functions of Tregs may be therapeutic in the treatment of autoimmune diseases. While recent studies demonstrated that natural Tregs are instable and dysfunctional in the inflammatory condition, induced Tregs (iTregs) may have a different feature. Here we review the progress of iTregs, particularly focus on their stability and function in the established autoimmune diseases. The advantage of iTregs as therapeutics used under inflammatory conditions is highlighted. Proper generation and manipulation of iTregs used for cellular therapy may provide a promise for the treatment of many autoimmune and inflammatory diseases.